<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Aesthetics Product Guide &#187; Pfizer Inc</title>
	<atom:link href="http://www.aestheticsproductguide.com/blog/tag/pfizer-inc/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.aestheticsproductguide.com/blog</link>
	<description>A comprehensive guide to aesthetics products for medical professionals</description>
	<lastBuildDate>Mon, 26 Jul 2010 04:57:22 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma</title>
		<link>http://www.aestheticsproductguide.com/blog/2010/01/12/pfizer-and-debiopharm-collaborate-to-co-develop-investigational-compound-tremelimumab-cp-675206-in-advanced-melanoma/</link>
		<comments>http://www.aestheticsproductguide.com/blog/2010/01/12/pfizer-and-debiopharm-collaborate-to-co-develop-investigational-compound-tremelimumab-cp-675206-in-advanced-melanoma/#comments</comments>
		<pubDate>Tue, 12 Jan 2010 05:54:31 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[206)]]></category>
		<category><![CDATA[anti-CTLA4 monoclonal antibody]]></category>
		<category><![CDATA[Debiopharm Group™]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[tremelimumab (CP675]]></category>

		<guid isPermaLink="false">http://www.aestheticsproductguide.com/blog/?p=224</guid>
		<description><![CDATA[Pfizer Inc and Debiopharm Group™ have announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.aestheticsproductguide.com/blog/wp-content/uploads/2010/01/Pfizer.png"><img class="alignleft size-full wp-image-225" style="margin: 5px" src="http://www.aestheticsproductguide.com/blog/wp-content/uploads/2010/01/Pfizer.png" border="0" alt="Pfizer" width="200" height="112" /></a>Pfizer Inc and Debiopharm Group™ have announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for its worldwide commercialization.</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/175582.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.aestheticsproductguide.com/blog/2010/01/12/pfizer-and-debiopharm-collaborate-to-co-develop-investigational-compound-tremelimumab-cp-675206-in-advanced-melanoma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
